Experimental Treatment Targets Missing Teeth
Scientists in Japan are testing a new medicine that may one day help humans grow missing teeth again.
The experimental treatment is called TRG-035. It has been developed by Japanese biotech startup Toregem BioPharma. The medicine is being studied as a possible future alternative to dentures and dental implants.
Kyoto University Hospital launched the first human clinical trial of the treatment. The early-stage trial is focused mainly on safety. Researchers want to understand how the drug behaves in the human body before wider testing begins.
The treatment is based on the idea that humans may still have dormant tooth buds. These are early tooth-forming structures that usually remain inactive after adult teeth develop.
Humans normally grow two sets of teeth during life. The first set includes baby teeth. The second set includes permanent adult teeth. Researchers believe a hidden biological pathway may allow another set of teeth to grow if the right signal is activated.
How the Tooth-Regrowth Drug Works
TRG-035 works by blocking a protein linked to stopping tooth development. This protein acts like an off-switch after adult teeth have grown.
By blocking that signal, researchers hope the body can restart natural tooth-growth activity. The medicine is designed to reactivate tooth buds and support the formation of new teeth.
The science behind the treatment was first tested in animals. Earlier research showed that mice could grow extra teeth when the tooth-blocking mechanism was removed. Later studies in animals, including ferrets, also showed promising results.
These findings encouraged researchers to move toward human testing.
The first safety trial involved adult men who were missing at least one tooth. Researchers do not expect these early participants to regrow teeth during the first phase. The goal is to confirm safety, study dosage and prepare for future trials.
Children With Missing Teeth May Be First Beneficiaries
If the safety results are positive, the next phase may focus on children born with missing teeth.
Researchers are especially interested in helping children aged 2 to 7 who have congenital tooth loss. The first priority may be children missing six or more teeth from birth.
For such children, missing teeth can affect chewing, nutrition, speech and facial development. A medicine that helps natural teeth grow could offer a major medical breakthrough.
Toregem BioPharma hopes the treatment can become commercially available by 2030 if clinical trials are successful.
At first, the drug is expected to target congenital tooth loss. Later, researchers hope it may also help adults who lost teeth due to decay, injury or ageing.
Experts say more research is still needed. The medicine must prove safe and effective in larger human trials before it can become a standard dental treatment.
Still, the trial has raised major hopes in regenerative dentistry. If successful, it could change how dentists treat missing teeth and improve quality of life for millions of people worldwide.
